News of Note—Inovio's MERS vaccine, Inimmune's NIH grant and more

non
(Pixabay)

Here is some other vaccine news of note for the week:

> In a phase 1 study, Inovio and GeneOne Life Science's MERS vaccine, dubbed INO-4700, induced high levels of antibody responses in roughly 95% of subjects and generated broad-based T-cell responses in nearly 90% of study participants. Release

> The University of Montana and startup Inimmune landed a $5.4 million grant from the NIH to develop a vaccine to fight the P. aeruginosa bacteria. Missoula Current article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Allergy Therapeutics’ grass pollen allergy vaccine Pollinex Quattro Grass showed significant and long-lasting symptom improvements three to six years after cessation of treatment. Precision Vaccinations article

 

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.